Evidence map›Paper›PMID 35910835›Full record

ArticleOxidative medicine and cellular longevity2022

DRDB: A Machine Learning Platform to Predict Chemical-Protein Interactions towards Diabetic Retinopathy.

Yu Wei, Ruili Zhang, Xiaoqiang Li, Zhonglin Li, Kaimin Guo, Shanshan Li, Li Yan, Qian Zhao, Baijian Qu, Wenjia Wang and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yu WeiState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0002-9262-6961
Ruili ZhangState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0002-0667-2524
Xiaoqiang LiCloudphar Pharmaceuticals Co., Ltd., Shenzhen, China.ORCID https://orcid.org/0000-0003-3136-5590
Zhonglin LiState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0001-9732-1895
Kaimin GuoCloudphar Pharmaceuticals Co., Ltd., Shenzhen, China.ORCID https://orcid.org/0000-0001-8069-7300
Shanshan LiState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0001-5116-3588
Li YanState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0002-0643-2379
Qian ZhaoCloudphar Pharmaceuticals Co., Ltd., Shenzhen, China.ORCID https://orcid.org/0000-0003-4724-1525
Baijian QuState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0003-1016-356X
Wenjia WangCloudphar Pharmaceuticals Co., Ltd., Shenzhen, China.
Shuiping ZhouThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd., No. 1, Tingjiang West Road, Beichen District, Tianjin 300410, China.
He SunCloudphar Pharmaceuticals Co., Ltd., Shenzhen, China.
Jianping LinState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0001-6974-0072
Yunhui HuCloudphar Pharmaceuticals Co., Ltd., Shenzhen, China.ORCID https://orcid.org/0000-0002-4966-1075
Nankai University · CNCloud Computing Center · CNTasly Holding Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR), a diabetic microangiopathy caused by diabetes, affects approximately 93 million people, worldwide. However, the drugs used to treat DR have limited efficacy and the variety of side effects. This is possibly because the complicated pathogenesis of DR is associated with multiple proteins. In this work, we attempted to identify potential drugs against DR-associated proteins and predict potential targets for drugs using in silico prediction of chemical-protein interactions (CPI) based on multitarget quantitative structure-activity relationship (mt-QSAR) method. Therefore, we developed 128 binary classifiers to predict the CPI for 15 DR targets using random forest (RF),

Indexed as

Diabetes MellitusDiabetic RetinopathyAlgorithmsHumansMachine LearningProteinsQuantitative Structure-Activity RelationshipProteins

Identifiers

PMID35910835
PMCPMC9329024
OpenAlexW4286009127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.